APPENDIX 3: FULL TEXT SCREENING CHECKLIST

a) Clinical Review

1. **Did this article include patients presenting in the ED with chest pain who are suspected to have ACS or AMI?**
   - ☐ Yes (include)
   - ☐ No (exclude)
   - ☐ Maybe (include)

2. **Is the article the primary report of the final results from a:**
   - ☐ RCT (include)
   - ☐ Non-RCT (include)
   - ☐ Meta-analysis / systematic review, or HTA (include)
   - ☐ Comparative observational study (include)
   - ☐ All other study types (exclude)
   - ☐ Can't decide (include)

3. **What comparator is used in the study?**
   - ☐ cTnT (include)
   - ☐ cTnI (include all non–point-of-care assays or Siemens Stratus CS point-of-care assay))
   - ☐ Cardiac ischemia biomarkers other than troponin (exclude)
   - ☐ No comparator (exclude)

4. **Include if the outcome of interest in the study is one of the following:**
   - ☐ Diagnostic test performance (including sensitivity, specificity, positive or negative likelihood ratios, positive or negative predictive values, AUC, rates of false-positive or false-negative tests, and test accuracy)
   - ☐ Thromboembolic events (e.g., VTE, DVT, PE)
   - ☐ Acute cardiovascular events (e.g., ACS, AMI)
   - ☐ Chronic / non-acute cardiovascular events (e.g., coronary artery stenosis/narrowing seen on angiogram)
   - ☐ Revascularization procedures (e.g., angiograms, PCI, CABG)
   - ☐ ED time until diagnosis or detection of abnormal concentration
   - ☐ Heart failure
   - ☐ Quality of life
   - ☐ Death
   - ☐ 30-day readmission rate
   - ☐ 30-day recurrence rate
   - ☐ 30-day mortality
   - ☐ Any harm outcomes reported
   - ☐ None of the above (exclude)

5. Final Decision

- ☐ Include
- ☐ Exclude
- ☐ Non-English or unable to translate

Reason for Exclusion:

- ☐ Inappropriate study population
- ☐ Not study types of interest
- ☐ Not primary report of study
- ☐ Study description only
- ☐ No intervention of interest
- ☐ No/inappropriate control group
- ☐ No relevant outcomes

b) Economic Review

Author (Year): _____ **REF ID:** _____

Level 2 Screening Questions	Circle One	
Q1. Is this a primary economic evaluation?	Yes	No
Q2. Are costs measured?	Yes	No
Q3 Is effectiveness measured	Yes	No
Q4. Does the study evaluate laboratory testing for patients admitted to an ED who are suspected of having MI or ACS?	Yes	No
Q5. Is one of treatment comparators: a) hs-cTnT (Abbott ARCHITECT, Beckman Access, Siemens Vista) **or** b) hs-cTnI (Roche Cobas E, Roche Elecsys)	Yes Yes	No No
Q6. Is one of the treatment comparators: a) hs-cTnT (Abbott ARCHITECT, Beckman Access, Siemens Vista) **or** b) hs-cTnI (Roche Cobas E, Roche Elecsys) **or** c) Sensitive Troponin T (Roche Cobas H232, Roche, Elecsys TnT Gen 4, Roche Cardiac Reader cTnT) **or** d) Sensitive Troponin I (Abbott AxSYM ADV, Abbott ARCHITECT, Alere Triage Cardio2, Alere Triage Cardio3, Beckman Access AccuTnI, bioMérieux Vidas Ultra, Ortho Vitros ECi ES, Siemens Centaur XP Ultra, Siemens Dimension RxL, Siemens Dimension Vista, Siemens Immulite 2500, Siemens Stratus CS)	Yes Yes Yes Yes	No No No No
Include study for review	Yes	No

Reason for Exclusion:

Check One if Study Was Excluded	
1. Neither costs or effects evaluated	
2. Cost-study only (no effectiveness measured)	
3. hs-cTnI or hs-cTnT were not comparators	
4. Other	